Almazov Centre participates in 14 scientific platforms of the Russian Ministry of Health and its specialists are included in the expert groups in six of these platforms. The research teams of the Centre were actively involved in shaping the research topics for these platforms. In 2019, the Centre carried out research work on 52 scientific topics as part of the state assignment on science. The Centre has 880.25 scientific staff positions, 112 research departments and laboratories. The total Hirsch index of the research staff is 1,446.
Following the state assignment, the Centre published 401 articles in journals, mostly with an impact factor of more than 0.3. The overall impact factor of the publications made in 2019 was 904.728 (as compared to 137 in 2014, 208.1 in 2015, 300.6 in 2016, 411.4 in 2017 and 528.2 in 2018 respectively). As part of the applied research, the Centre continued to develop the prototypes of medical devices and new drugs, conducted the preclinical trials of the drug based on succinic acid for the treatment of osteoporosis, developed the approaches for targeted drug delivery by inorganic nanocarriers. Twenty-two patents were obtained and 25 more patent applications were filed based on the results of 2019. Quarterly and annual publication performance (defined as the number of publications in top-tier journals per researcher) was regularly above the standard established for research institutions.
In 2019, Almazov Centre carried out research under 11 grants received from the Russian Science Foundation, 18 grants from the Russian Foundation for Basic Research and 3 grants from the Russian Ministry of Science and Higher Education.
More than 400 abstracts were published at major scientific conferences and more than 30 presentations were made at World or European congresses. Fifty-one scientific and practical events were organized. The Centre’s researchers are members of international expert communities and editorial boards for major European magazines. They referee articles in various publishing systems and are included in the working groups preparing the international clinical guidelines as well as in expert councils and scientific program committees of major international congresses and conferences. The Centre is proud to have 1 Academician, 2 corresponding members and 4 professors of the Russian Academy of Sciences.
In 2019, Almazov Centre held a number of international congresses, conferences and events with international participation, including the Scientific Session of the Translational Medicine Cluster, All-Russian scientific and practical conference Polenov’s Readings, Saint Petersburg Forum — How to Fight Obesity and Type 2 Diabetes: Patient Focus, 7th Global Educational Forum Russian Cardiovascular Days, 3rd interregional conference Drug Safety: Basic and Applied Issues, all-Russian Conference with international participation Patient-Centered Technologies in Perinatology and Pediatrics, Interdisciplinary Conference Central Nervous System Tumors in Children: Diagnostic Difficulties and Treatment Prospects, 2nd Saint Petersburg Lymphology Forum – 21st Century Lymphology: New Approaches and Relevant Research, Regional Forum of Cardiology and Cardiovascular Surgery, 3rd Interdisciplinary conference Orphan Diseases: Diagnostics, Treatment, Rehabilitation, and more.
The researchers and clinicians of the Centre gave presentations, presented posters and served as chairs of scientific symposia at international congresses and conferences.
Since 2017, the Preclinical Translational Research Centre has been operating within the structure of Almazov Centre. It comprises the SPF laboratory animal facility designed for testing the safety and efficacy of new drug compounds in accordance with global standards. The work of the research laboratory units of this Centre complies with international GLP regulations.
The Preclinical Translational Research Centre provides the opportunity to conduct unique experimental studies in compliance with all international regulations. Experimental studies of any complexity are possible here, including the development and testing of new drugs and biotechnological products, the creation of new experimental models. The laboratory unit of the Preclinical Translational Research Centre enables assessing the acute and chronic toxicity of drug compounds, their carcinogenicity, embryo- and immunotoxicity, as well as monitoring drug interaction with specific molecular targets.